https://www.thebodypro.com/category/prep-hiv-pre-exposure-prophylasxis/tag/croi-conference-on-retroviruses-and-opportunistic-infections
PrEP (HIV Pre-Exposure Prophylaxis)

CROI (Conference on Retroviruses and Opportunistic Infections)

The Latest

David Alain Wohl recaps CROI 2021 research during a video interview

CROI 2021 Highlights: New HIV Research With Clinical Impact

Here's a walkthrough of some of the most compelling stories coming out of the year's biggest HIV science meeting to date.

By Myles Helfand
photo of David Alain Wohl, M.D., as he recaps research from CROI 2021

As CROI 2021 Attests, the PrEP Revolution Is Coming

Analysis from David Alain Wohl, M.D., on new research in on HIV prevention, especially in areas that will expand and transform PrEP options.

By David Alain Wohl, M.D.
injectable

Long-Acting ART Is Here. How Do We Make It Work for Our Patients?

Injectable HIV interventions are a game-changing new option for people dealing with pill fatigue, but there are implementation challenges for clinicians to consider.

By Larry Buhl
injection vials

Long-Acting HIV Treatment and PrEP Pipeline Update: So Many Formulations!

CROI 2021 featured new research on a host of long-acting antiretrovirals in development, including less-frequent treatment injections, a weekly pill for HIV treatment, injectable PrEP, vaginal PrEP rings, and PrEP implants.

By Larry Buhl
Researchers on a Zoom meeting during a CROI 2021 press conference

CROI 2021 Data Bites: HIV Prevention and Epidemiology

From new forms of PrEP to new data on HIV in the U.S., CROI 2021 has plenty of developments to report when it comes to preventing HIV and better understanding the drivers of the modern epidemic.

By Myles Helfand and Larry Buhl
pill bottles and cash

A PrEP Pricing Pickle: Descovy Will Need a Drastic Discount to Be Worthwhile, Study Finds

With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.

By Myles Helfand
Staying on PrEP is Significantly Different for PrEP Users With Commercial Insurance Versus Medicaid Img

Staying on PrEP is Significantly Different for PrEP Users With Commercial Insurance Versus Medicaid

Young adults, blacks, cisgender women, and people in rural areas, as well as people on Medicaid, were less likely to persist on PrEP.

By Stephen Hicks
Promo Image

CROI 2019: What News to Expect in HIV Science and Policy

TheBodyPro is covering all the latest in HIV science at the biggest annual gathering of HIV researchers in the U.S. Here's a preview of what's to come.

By Sony Salzman
Retaining Patients in PrEP Care Faces Many Hurdles, Studies Show Img

Retaining Patients in PrEP Care Faces Many Hurdles, Studies Show

Most people who could benefit from pre-exposure prophylaxis are not accessing it, the U.S. Centers for Disease Control and Prevention revealed at this year's Conference on Retroviruses and Opportunistic Infections.

By Barbara Jungwirth
Attendees in the poster hall at CROI 2018

Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence

When is a pre-exposure prophylaxis (PrEP) failure actually a provider failure? And how do we tell the difference?

By Damon L. Jacobs, L.M.F.T.